Advanced biliary tract cancer(BTC)and pancreatic ductal adenocarcinoma(PDAC)have poor prognoses and limited treatment options.Here,we conducted thisfirst-in-class phase II study to evaluate the efficacy and safety of ...
supported by Jiangsu Hengrui Pharmaceuticals and the following grants:the National Natural Science Foundation of China(NSFC:82321003,82173128,82073377,81930065);the Natural Science Foundation of Guangdong(2021A1515012439);Guangdong Basic and Applied Basic Research Foundation(2024B1515020120);the CAMS Innovation Fund for Medical Sciences(CIFMS:2019-I2M-5-036);Additional funding was provided by the Cancer Innovative Research Program of Sun Yat-sen University Cancer Center(CIRP-SYSUCC-0004).
This phase 2/3 trial (NCT04856787) assessed the efficacy and safety of SHR-1701, a bifunctional protein targeting PD-L1 and TGF-β,in combination with BP102 (a bevacizumab biosimilar) and XELOX (capecitabine plus oxal...
Key R&D Program of Xizang Autonomous Region(XZ202101ZY0004G);National Natural Science Foundation of China(U2142202);National Key R&D Program of China(2022YFC3004104);Key Innovation Team of China Meteor-ological Administration(CMA2022ZD07)。
Short-duration heavy rainfall(SHR),as delineated by the National Meteorological Center of the China Me-teorological Administration,is characterized by hourly rainfall amounts no less than 20.0 mm.SHR is one of the mos...
This study was funded by Jiangsu Hengrui Pharmaceuticals.
A dose-escalation and expansion,phase 1/2 study(ClinicalTrials.gov,NCT04818333)was conducted to assess the novel antibodydrug conjugate SHR-A1811 in pretreated HER2-altered advanced non-small cell lung cancer(NSCLC).H...